Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - STADA Arzneimittel AG: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016

Company: STADA Arzneimittel AG Date: 2016-05-13 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Corporate | 13 May 2016 10:00

#   

STADA Arzneimittel AG: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous  

  

2016-05-13 / 10:00  

The issuer is solely responsible for the content of this announcement.  

  

- - -

**Press Release**

**STADA: STADA allows elaborated motion from Active Ownership Fund as supplement to the Annual General Meeting 2016**

Bad Vilbel, May 13, 2016 – STADA Arzneimittel AG has received an elaborated motion from Active Ownership Fund SICAV-FIS SCS as a supplement to the agenda of the STADA Annual General Meeting 2016. STADA conducted a review of the motion and published it on its website.

On May 6, 2016, Active Ownership Fund had submitted an agenda amendment motion to the Company, which the investor has now elaborated on. Accordingly, the investor now proposes three instead of five new candidates for election as shareholder representatives on the Supervisory Board.

Within the scope of its discretionary powers, the STADA Executive Board decided to allow the agenda amendment motion in order to avoid the substantial costs that would have been incurred in the case of legal action from Active Ownership Fund to assert their request or the convening of an extraordinary Annual General Meeting.

The Executive Board sees its obligations first and foremost in the well-being of the company. For this reason, it would like to ensure a quick decision in this matter. The Executive Board can thus concentrate on the further implementation of the successful growth strategy in order to create value for the company’s shareholders.

It is now up to the shareholders to vote on the motion from Active Ownership Fund at the Annual General Meeting on June 9, 2016.

STADA Chairman of the Supervisory Board Dr. Martin Abend commented on the elaborated motion as follows: “In the interest of good corporate governance, it is important to us that Supervisory Board members are elected at the Annual General Meeting. Because we on the Supervisory Board had already begun to look at questions related to the succession planning process some time ago, a constructive dialog about the qualified candidates, which I welcome, has taken place with Active Ownership Fund”.

Additional information for analysts:  

STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /  

Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: [ir@stada.de](mailto:ir@stada.de)

Additional information for journalists:  

STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /  

Tel.: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: [press@stada.de](mailto:press@stada.de)

Or visit us in the Internet at [www.stada.com](http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=d7bf7f62d071a6ce7dbc2f322548448a&application_id=463571&site_id=news_data&application_name=news) .

  

- - -

2016-05-13 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Media archive at www.dgap-medientreff.de and www.dgap.de  

- - -

|     |     |
| --- | --- |
| Language: | English |
| Company: | STADA Arzneimittel AG |
|     | Stadastraße 2-18 |
|     | 61118 Bad Vilbel |
|     | Germany |
| Phone: | +49 (0)6101 603- 113 |
| Fax: | +49 (0)6101 603- 506 |
| E-mail: | communications@stada.de |
| Internet: | www.stada.de |
| ISIN: | DE0007251803, DE0007251845, |
| WKN: | 725180, 725184, |
| Indices: | MDAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX |
|     |     |     |

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

![show this](http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=463571&application_name=news&site_id=news_data)